Maintenance therapy is now clinically proven to postpone disease progression in advanced CTCL which could significantly change current clinical practice
- RESMAIN is one of the largest clinical trials in cutaneous T-cell lymphoma (CTCL) to-date
- Resminostat (Kinselby) as a maintenance treatment for advanced CTCL, is clinically proven to postpone disease progression in patients – a new treatment paradigm in CTCL
- Resminostat (Kinselby) treatment has shown a statistically significant improvement in progression free survival of 97.6% compared to placebo, with a risk reduction of 38% in recently announced headline trial results (median PFS: 8.3 months versus 4.2 months; p=0.015; HR: 0.623 (95%CI: 0.424, 0.916)
- Resminostat (Kinselby)’s median time to next treatment (median TTNT) versus placebo showed a significant improvement, more than doubling to 8.8 months compared to 4.2 months; p= 0.002; HR: 594 (95% CI: 0.424, 0.916)
- The side effects of resminostat were mainly mild to moderate, manageable and reversible
Read more here…
